Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
CH did not affect survival in patients with mCRPC treated with ARPIs in A031201. H-CH and TET2-mutated CH were associated with more CVAEs. These findings inform the risk/benefit discussion about ARPIs in mCRPC.
Authors
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Irenaeus C.C. Chan (ORCID: https://orcid.org/0009-0004-3250-9626)
- Glenn Heller (ORCID: https://orcid.org/0000-0001-9217-8348)
- Catherine C. Coombs (ORCID: https://orcid.org/0000-0001-5615-2247)
- Kelly L. Bolton (ORCID: https://orcid.org/0000-0001-6584-3357)
- Brian C. Miller (ORCID: https://orcid.org/0000-0001-5931-4184)
- Olivia Bobek (ORCID: https://orcid.org/0000-0003-4922-1659)
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Himisha Beltran (ORCID: https://orcid.org/0000-0003-3259-2226)
- Todd E. Druley (ORCID: https://orcid.org/0000-0002-3245-7561)
- Jeffrey L. Jensen (ORCID: https://orcid.org/0000-0002-8821-4980)
- Matthew I. Milowsky (ORCID: https://orcid.org/0000-0002-8965-8129)
- David W. Hillman
Institutions
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Duke University (US)
- University of California, Irvine (US)
- Washington University in St. Louis (US)
- Kettering University (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- Irvine University (US)
- Mayo Clinic in Florida (US)
- UNC Lineberger Comprehensive Cancer Center
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0803
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- American Society of Clinical Oncology
- Celgene
- Movember Foundation
- TG Therapeutics
- Clovis Oncology
- Accuray
- MEI Pharma
- Mirati Therapeutics
- BeiGene
- G1 Therapeutics
- Seagen
- Astellas Pharma
- National Institutes of Health
- Genentech
- National Cancer Institute